TACC3 and neoplasm: Interestingly, the authors speculated that the coexistence of two different FGFR3 alterations (FGFR3-TACC3 fusion and FGFR3 amplification) in the same tumor could be the main reason for the significant efficacy of Anlotinib therapy and emphasized that tumors harboring FGFR3-TACC3 rearrangements and/or FGFR3 amplification should be selected for clinical trials featuring FGFR inhibitors (35).